Wójcicki J, Górnik W, Syrenicz A, Gawrońska-Szklarz B, Czekalski S
Zakładu Farmakologii Klinicznej.
Pol Tyg Lek. 1990;45(6-7):131-3.
Hyperthyroidic patients treated with methimazole were retrospectively divided into two groups, depending on the period of time required for euthyreosis: these attaining euthyreosis up to 28 days of therapy (A) and these in whom thyroid gland functioning is normalized after a 35-day therapy with full dose of methimazole (B). The study aimed at investigating whether clinical euthyreosis is related to the activity of microsomal enzymes in the liver using phenazone elimination test for this purpose. Phenazone elimination test was performed just before the treatment and after 8 weeks of methimazole administration. A decrease in kel and Clt as well as an increase in AUC were noted. These changes were more pronounced in patients of group A than those of group B. It might be concluded that phenazone pharmacokinetics is different in patients quickly attaining euthyreosis. The difference is probably due to the difference in biotransformation of methimazole in the liver in which microsomal enzymes play some role.
根据甲状腺功能正常化所需时间,将接受甲巯咪唑治疗的甲状腺功能亢进患者回顾性地分为两组:治疗28天内实现甲状腺功能正常的患者(A组)和使用全剂量甲巯咪唑治疗35天后甲状腺功能恢复正常的患者(B组)。本研究旨在通过非那宗消除试验调查临床甲状腺功能正常是否与肝脏微粒体酶活性有关。在治疗前和甲巯咪唑给药8周后进行非那宗消除试验。观察到kel和Clt降低以及AUC增加。这些变化在A组患者中比B组患者中更明显。可以得出结论,快速实现甲状腺功能正常的患者非那宗药代动力学不同。这种差异可能是由于肝脏中甲巯咪唑生物转化的差异,其中微粒体酶起了一定作用。